Lung, Phase I-II

An Open-Label, Phase 1/1b, Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Volunteers
Health Professionals

What is the purpose of this trial?

The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), preliminary antitumor ORIC-114 when administered to patients with advanced solid tumors harboring an EGFR or HER2 alteration.

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Jennifer Pope

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Sarah Goldberg, MD, MPH
Associate Professor of Internal Medicine (Medical Oncology); Associate Director, Medical Oncology-Hematology Program; Research Director, Center for Thoracic Cancers; Chief, Thoracic Oncology

Sub-Investigators

Last Updated
04/16/2024
Study HIC
#2000035136